Pharmacotherapeutics in the Critically Ill COVID-19 Patients
Main Article Content
Abstract
Pharmacotherapeutics are being repurposed and used as off-label at various stages of COVID-19 infection. Clinical trials are being initiated or are ongoing to investigate the effectiveness and safety of these pharmacotherapeutics. This review article outlines the current pharmacotherapeutics and the controversies surrounding their use. The pharmacotherapeutics that were discussed are hydroxychloroquine, favipiravir, lopinavir/ritonavir, remdesivir, interferons, tocilizumab, and steroids. We also discussed the special consideration for pharmacotherapeutics in COVID-19 infection. No pharmacotherapeutics have been found to be effective and approved for the treatment of COVID-19 infection. However, there are clinical trials that have eliminated the possibilities of use of some pharmacotherapeutics while others had shown promising preliminary results of its use.
Downloads
Article Details
References
World Health Organization. (2020). Clinical management of COVID-19: interim guidance, 27 May 2020. World Health Organization.
Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020; 323(18): 1824-1836.
Ray JL, Tau HL, David CBL. From SARS to COVID-19: the Singapore journey. Med J Aust. 2020 Jun; 212(11):497-502.e1.
Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14;369:m1849.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72–3.
Gautret P, Lagier J-C, Parola P, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar; 34:101663.
Downes K, Chiotos K, Fitzgerald J, Scheetz MH, Zuppa AF. Rational dosing of HCQ for COVID-19_pre-print. OSF Preprints [Internet]. 2020 [cited 2020 Jun 1]; Available from: https://osf.io/py3kv/
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet [Internet]. 2020 May 22; Available from: http://dx.doi.org/10.1016/S0140-6736(20)31180-6.
No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. [Internet]. [cited 2020 Jun 19]. Available from: https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19.
Restrepo AMH, Moorthy V, Preziosi M-P. Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients [Internet]. http://isrctn.com/. Available from: http://dx.doi.org/10.1186/isrctn83971151
Du YX. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019‐nCoV Infection. Clinical Pharmacology & Therapeutics; 2020.
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering. 2020.
Chen C, Zhang Y, Huang J, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. Preprint Med Rx IV; 2020.
Muhammad Tahir Q, Safar MA, Mubarak AA, Chena L. Structural basis of SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal plants. J Genet Genomics 2020; Feb 20;47(2):119-121.
Sheahan TP. Comparative Therapeutic Efficacy of Remdesivir and Combination Lopinavir, Ritonavir, and Interferon Beta Against MERS-CoV Nat Commun 2020; Jan 10;11(1):222.
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382:1787-1799.
Deng L, Li C, Zeng Q, et al. Arbidol Combined With LPV/r Versus LPV/r Alone Against Corona Virus Disease 2019: A Retrospective Cohort Study. J Infect. 2020; Mar 11.
Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial [published online ahead of print, 2020 May 8]. Lancet. 2020; S0140-6736(20)31042-4. doi:10.1016/S0140-6736(20)31042-4.
Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. The Lancet. 2020;395(10236):1569-1578, doi.org/10.1016/S0140-6736(20)31022-9.
Beigel JH, Kay M, Tomashek, et al. for the ACTT-1 Study Group Members. Remdesivir for the Treatment of Covid-19: Preliminary Report. NEJM. 2020. DOI: 10.1056/NEJMoa2007764.
Zhou Q, Chen V, Shannon CP, et al. Interferon-α2b Treatment for COVID-19. Front. Immunol. 2020; 11:1061. doi: 10.3389/fimmu.2020.01061
Sato K, Tsuchiya M, Saldanha J, et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993; 53:851–6.
Toshio T, Tadamitsu K. The biology and medical implications of Interleukin-6. Cancer Immunol Res. 2014;2(4):288-94.
Masahiko M, Keiko K, Makoto O, et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005; 5:1731-40.
Alexander SV, Philipp G, Marion S, et al. Cytokine release syndrome. J Immunother Cancer. 2018; 6:56-70.
Tanaka T, Narazaki M, Kishimoto T. Therapeutic targeting of the Interleukin-6 receptor. Annu Rev Pharmacol Toxicol. 2012; 52:199–219.
Micha L, Susan G, Nicolas F. Exposure-response relationship of Tocilizumab, an anti–IL-6 receptor monoclonal antibody, in a large population of patients with Rheumatoid Arthritis. J Clin Pharmacol. 2012;53(2):151 –9.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-1034.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;1-5.
Christina CP, Frederick LA, Yu S, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. 2020. https://doi.org/10.1016/j.chest.2020.06.006. Epub 2020/06/15.
National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 7); 2020. https://www.chinalawtranslate.com/coronavirus-treatment-plan-7. Epub 2020/03/04.
Ruggero C, Nicola DR, Flavia M, et al. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Eur J Intern Med. 2020; 76:31–5.
Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous Tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res. 2014;66(3):344-54.
Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-O’Callaghan A, Pardos-Gea J, Quintana A, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020;19(7): 102569.
Alhazzani W, Hyalander MM, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5): 854-887.
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; March 13: e200994.
Horby PW, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients With COVID-19 – Preliminary Report. medRxiv Preprint 2020. [Epub Ahead of Print].
Naksuk N, Lazar S, Peeraphatdit TB. Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. Eur Heart J Acute Cardiovasc Care. 2020 Apr;9(3):215–21.
Fernandez AP. Updated recommendations on the use of hydroxychloroquine in dermatologic practice. J Am Acad Dermatol. 2017 Jun;76(6):1176–82.
Mantovani A, Beatrice G, Dalbeni A. Coronavirus disease 2019 and prevalence of chronic liver disease: A meta-analysis [Internet]. Vol. 40, Liver International. 2020. p. 1316–20. Available from: http://dx.doi.org/10.1111/liv.14465
Sun J, Deng X, Chen X, et al. Incidence of Adverse Drug Reactions in COVID-19 Patients in China: An Active Monitoring Study by Hospital Pharmacovigilance System. Clin Pharmacol Ther [Internet]. 2020 Apr 23; Available from: http://dx.doi.org/10.1002/cpt.1866.
Olry A, Meunier L, Délire B, Larrey D, Horsmans Y, Le Louët H. Drug-Induced Liver Injury and COVID-19 Infection: The Rules Remain the Same [Internet]. Drug Safety. 2020. Available from: http://dx.doi.org/10.1007/s40264-020-00954-z.
Hirsch JS, Ng JH, Ross DW, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int [Internet]. 2020 May 16; Available from: http://dx.doi.org/10.1016/j.kint.2020.05.006.
Adamsick ML, Gandhi RG, Bidell MR, et al. Remdesivir in Patients with Acute or Chronic Kidney Disease and COVID-19. J Am Soc Nephrol [Internet]. 2020 Jun 8; Available from: http://dx.doi.org/10.1681/ASN.2020050589.
Browning DJ, Easterbrook M, Lee C. The 2016 American Academy of Ophthalmology Hydroxychloroquine Dosing Guidelines For Short, Obese Patients. Ophthalmol Retina. 2019 Oct;3(10):809–13.
Madelain V, Le MP, Champenois K, et al. Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case–control study [Internet]. Journal of Antimicrobial Chemotherapy. 2017. p. dkw527. Available from: http://dx.doi.org/10.1093/jac/dkw527.
Pappas DA, Etzel CJ, Crabtree M, et al. Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis is Unaffected by Comorbidity Burden or Obesity: Data from a US Registry. J Rheumatol [Internet]. 2020 Jan 15; Available from: http://dx.doi.org/10.3899/jrheum.190282.
Favilli A, Mattei GM, Raspa F, et al. Effectiveness and safety of available treatments for COVID-19 during pregnancy: a critical review. J Matern Fetal Neonatal Med. 2020 Jun 7;1–14.
Avigan英文仿單 [Internet]. [cited 2020 Jun 13]. Available from: https://www.cdc.gov.tw/File/Get/ht8jUiB_MI-aKnlwstwzvw.